Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:31:29.774Z.
Calculation as of: 2026-10-06T13:31:29.774Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$120.44M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$130.79M
EBITDA Yield
1.34%
TTM Avg
1.37%
3Y Avg
1.37%
5Y Avg
1.37%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $125.27M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.00M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $129.76M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $120.44M | N/A | N/A | N/A | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | 1.34% | 1.37% | 1.37% | 1.37% |
| Entera Bio Ltd. (ENTX)vs › | $131.11M | N/A | 27.23% | 27.23% | 27.23% |
| BGM Group Ltd. (BGM)vs › | $118.63M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $133.00M | N/A | 4.68% | 4.68% | 4.68% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
